anti-Tumor Necrosis Factor Receptor Superfamily, Member 17 (TNFRSF17) Antibodies

The protein encoded by TNFRSF17 is a member of the TNF-receptor superfamily. Additionally we are shipping TNFRSF17 Proteins (68) and TNFRSF17 Kits (26) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
TNFRSF17 287034  
TNFRSF17 608 Q02223
TNFRSF17 21935 O88472
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-TNFRSF17 Antibodies at antibodies-online.com

Showing 10 out of 137 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Cow Rabbit Un-conjugated WB 100 μL Log in to see 2 to 3 Days
$289.00
Details
Mouse Rabbit Un-conjugated WB Western blot analysis of BCMA expression in K562 (Lane 1) and U937 (Lane 2) cell lysate. 100 μg Log in to see 2 to 3 Days
$265.00
Details
Human Rabbit Un-conjugated WB Western blot analysis of CD269 expression in HEK293T (A), Raw264.7 (B), PC12 (C) whole cell lysates. 200 μL Log in to see 13 to 14 Days
$487.50
Details
Mouse Rat Fluorescein FACS Detection of BCMA/TNFRSF17 in Mouse Splenocytes by Flow Cytometry. Mouse splenocytes were stained with Rat Anti-Mouse BCMA/TNFRSF17 Fluorescein-conjugated Monoclonal Antibody. Quadrant markers were set based on control antibody staining. 100 Tests Log in to see 8 to 9 Days
$276.85
Details
Human Rat Un-conjugated BP, ELISA, FACS, ICC, IF, IHC, Neut, WB Flow Cytometry: BCMA/TNFRSF17 Antibody (Vicky-1) [NBP1-97637] - Analysis using the PE conjugate of NBP1-97637. Staining of 10^6 U266 cells using BCMA (human), mAb (Vicky-1) (PE conjugate) at a concentration of 10ug/ml. Flow Cytometry: BCMA/TNFRSF17 Antibody (Vicky-1) [NBP1-97637] - Detection of endogenous human BCMA with MAb to BCMA (human) (Vicky-1). Method: U266 cells (2x10^5) were incubated on ice for 30 min. with 0.2ug of MAb to BCMA (human) (Vicky-1) or an isotype control in 25ul FACS buffer (PBS, 5% fetal calf serum, 0.02% azide). The primary antibody was revealed with PAb to Rat IgG (R-PE) and then analyzed by flow cytometry. 0.05 mg Log in to see 7 to 9 Days
$488.73
Details
Human Goat Un-conjugated BR, CyTOF, ELISA (Capture), FACS, WB Detection of BCMA/TNFRSF17 in U266 Human Cell Line by Flow Cytometry. U266 human myeloma cell line was stained with Goat Anti-Human/Primate BCMA/ TNFRSF17 Antigen Affinity-purified Polyclonal Antibody. 100 μg Log in to see 8 to 9 Days
$435.05
Details
Human Goat PE FACS Detection of BCMA/TNFRSF17 in RPMI 8226 Human Cell Line by Flow Cytometry. RPMI 8226 human multiple myeloma cell line was stained with Goat Anti-Human BCMA/TNFRSF17 PE-conjugated Antigen Affinity-purified Polyclonal Antibody. 100 Tests Log in to see 8 to 9 Days
$363.86
Details
Human Rabbit Un-conjugated EIA, WB TNFRSF17 Antibody (Center) western blot analysis in MDA-MB231 cell line lysates (35 µg/lane). This demonstrates the TNFRSF17 antibody detected the TNFRSF17 protein (arrow). 0.4 mL Log in to see 6 to 8 Days
$484.00
Details
Human Rabbit Un-conjugated ELISA, ICC, IF, WB ABIN6272668 staining Hela by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) Ab, diluted at 1/600, was used as the secondary antibody. Western blot analysis of TNFRSF17 using Jurkat whole cell lysates 100 μL Log in to see 11 to 12 Days
$390.77
Details
Human Goat Fluorescein FACS Detection of BCMA/TNFRSF17 in RPMI 8226 Human Cell Line by Flow Cytometry. RPMI 8226 human multiple myeloma cell line was stained with Goat Anti-Human BCMA/TNFRSF17 Fluorescein-conjugated Antigen Affinity-purified Polyclonal Antibody. 100 Tests Log in to see 8 to 9 Days
$276.85
Details

Top referenced anti-TNFRSF17 Antibodies

  1. Mouse (Murine) Monoclonal TNFRSF17 Primary Antibody for FACS - ABIN4895658 : Notley, Baker, Ehrenstein: Secreted IgM enhances B cell receptor signaling and promotes splenic but impairs peritoneal B cell survival. in Journal of immunology (Baltimore, Md. : 1950) 2010 (PubMed)
    Show all 6 Pubmed References

  2. Human Polyclonal TNFRSF17 Primary Antibody for BR, CyTOF - ABIN5012843 : Tai, Li, Breitkreutz, Song, Neri, Catley, Podar, Hideshima, Chauhan, Raje, Schlossman, Richardson, Munshi, Anderson: Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. in Cancer research 2006 (PubMed)
    Show all 5 Pubmed References

  3. Human Polyclonal TNFRSF17 Primary Antibody for ELISA (Detection), FACS - ABIN4899163 : Moir, Malaspina, Pickeral, Donoghue, Vasquez, Miller, Krishnan, Planta, Turney, Justement, Kottilil, Dybul, Mican, Kovacs, Chun, Birse, Fauci: Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. in The Journal of experimental medicine 2004 (PubMed)
    Show all 5 Pubmed References

  4. Human Polyclonal TNFRSF17 Primary Antibody for FACS - ABIN4895686 : Frigyesi, Adolfsson, Ali, Christophersen, Johnsson, Turesson, Gullberg, Hansson, Nilsson: Robust isolation of malignant plasma cells in multiple myeloma. in Blood 2014 (PubMed)
    Show all 4 Pubmed References

  5. Human Monoclonal TNFRSF17 Primary Antibody for BP, ELISA - ABIN4283793 : Sakurai, Hase, Kanno, Kojima, Okumura, Kobata: TACI regulates IgA production by APRIL in collaboration with HSPG. in Blood 2007 (PubMed)
    Show all 3 Pubmed References

  6. Human Monoclonal TNFRSF17 Primary Antibody for FACS - ABIN4255822 : Lyu, Rai, Ahn, Sung, Cheung, Marks, Aggarwal, Aguiar, Gandhi, Rosenblum: The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. in Neoplasia (New York, N.Y.) 2010 (PubMed)
    Show all 2 Pubmed References

  7. Mouse (Murine) Monoclonal TNFRSF17 Primary Antibody for BP, FACS - ABIN4283791 : Hardenberg, Fernandez, Hendriks, Chebli, Jacquet, Sitbon, Hahne, Medema: APRIL facilitates viral-induced erythroleukemia but is dispensable for T cell immunity and lymphomagenesis. in Journal of leukocyte biology 2008 (PubMed)

  8. Human Polyclonal TNFRSF17 Primary Antibody for FACS - ABIN4895684 : Bloom, Chang, Pauly, Kwun, Fechner, Hayes, Samaniego, Knechtle: BAFF is increased in renal transplant patients following treatment with alemtuzumab. in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009 (PubMed)

More Antibodies against TNFRSF17 Interaction Partners

Human Tumor Necrosis Factor Receptor Superfamily, Member 17 (TNFRSF17) interaction partners

  1. Expression patterns of BAFF and its receptor BCMA differ according to lupus nephritis class.

  2. High BCMA expression is associated with primary central nervous system lymphoma.

  3. soluble BCMA sequesters circulating BAFF, thereby preventing it from performing its signaling to stimulate normal B-cell and plasma cell development, resulting in reduced polyclonal antibody levels in multiple myeloma patients.

  4. Studied expression of B-cell maturation antigen (BCMA) in osteoblasts and the toxic effect of chromium on its expression; found BCMA is involved in osteogenesis of osteoblasts; chromium downregulates expression of BCMA in osteoblasts.

  5. BCMA has other contributors for ligands binding except DxL motif. The affinity of BCMA for APRIL higher than for BAFF may be caused by the segment outside of the conservative DxL motif. Moreover, the exposition of new binding modes of BCMA2 interacting with APRIL may establish the foundation of designing novel drugs in the future

  6. New molecular mechanisms of in vivo Multiple Myeloma (MM) growth and immunosuppression critically dependent on BCMA and APRIL in the Bone marrow microenvironment, further supporting targeting this prominent pathway in MM.

  7. We have identified a specific serum protein, BCMA, as a novel independent marker for both monitoring and predicting outcomes for MM patients. We have shown that sBCMA is elevated in MM patients, and can be used to follow their disease status, PFS and OS.

  8. The expression levels of serum BAFF and the three receptors (TACI, BCMA and BAFF-R) in non-Hodgkin lymphoma patients were significantly higher than in healthy controls.

  9. Decreased BCMA expression on peripheral B cells according to severe disease activity suggests that BCMA plays an important regulating role in B-cell hyperactivity and immune tolerance homeostasis in systemic lupus erythematosus patients

  10. results suggest that Akt and JNK pathways are involved in the regulation of B-cell maturation antigen (BCMA)

  11. shedding of BCMA by gamma-secretase controls plasma cells in the bone marrow and yields a potential biomarker for B-cell involvement in human autoimmune diseases

  12. elevated serum levels in patients with Behcet's disease

  13. Data show significant differences in expression of tumour necrosis factor family (BAFF) receptors BAFF-R, BCMA and TACI in patients with and without anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies.

  14. High BCMA expression is associated with breast cancer.

  15. BAFF and APRIL as well as their cognate receptors (BCMA, TACI) correlate with glioma grade. (Meta-analysis)

  16. The B cell maturation antigen (BCMA) is a tumor necrosis family receptor member that is predominantly expressed on terminally differentiated B cells and, upon binding to its ligands B cell activator of the TNF family and a proliferation inducing ligand.

  17. Activation of B cells through BCMA regulates spinal cord injury-induced autoimmunity via a proliferation-inducing ligand (APRIL) and B-cell-activating factor (BAFF).

  18. Data indicate that MAGE3, Survivin and B-cell maturation antigen (BCMA) mRNA-pulsed dendritic cells (DCs) are capable of stimulating tumor-associated antigens (TAA)-specific T-cell responses in multiple myeloma (MM) patients.

  19. Data indicate that B-cell maturation antigen (BCMA) is a suitable target for chimeric antigen receptor (CAR)-expressing T cells, and adoptive transfer of anti-BCMA-CAR-expressing T cells is a promising new strategy for treating multiple myeloma.

  20. B-cell maturation antigen (BCMA), an essential membrane protein for maintaining the survival of plasma cells, was identified as a glycoprotein exhibiting complex-type N-glycans at a single N-glycosylation site, asparagine 42.

Mouse (Murine) Tumor Necrosis Factor Receptor Superfamily, Member 17 (TNFRSF17) interaction partners

  1. high affinity antibody blocks the binding of the native ligands APRIL and BAFF to BCMA. This finding is rationalized by the high resolution crystal structure of the Fab fragment in complex with the extracellular domain of BCMA

  2. Elimination of B lymphocyte stimulator receptor 3 (BR-3) and BCMA inhibits the development of SLE in NZM mice.

  3. we have identified a novel role for BCMA to control excess BAFF production in murine lupus through restraining the accumulation of BAFF-producing neutrophils.

  4. Heteromers consisting of one BAFF and two APRIL bind to receptor TACI, BCMA but not to BAFFR.

  5. BCMA is dispensable for the development of SLE in NZM mice. BAFF-BCMA interactions contribute to SLE.

  6. Study reveals that BCMA works to control B cell homeostasis and self-tolerance in systemic autoimmunity.

  7. Blimp-1 is a positive regulator of the expression of BCMA gene in mouse plasma cells.

  8. The 5'-flanking sequence from -820 to +145 bp of BCMA is of promoter activity.

  9. A vital role of BCMA in bone marrow plasma cell survival.

  10. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells.

  11. Review. APRIL interactions with BCMA likely govern memory B cell populations.

  12. Review. Direct BAFF/APRIL signalling in T cells and/or T cell modulation in response to a BAFF-modified B cell compartment may play an important role in inflammation and immunomodulation.

TNFRSF17 Antigen Profile

Protein Summary

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation.

Gene names and symbols associated with TNFRSF17

  • TNF receptor superfamily member 17 (Tnfrsf17) antibody
  • TNF receptor superfamily member 17 (TNFRSF17) antibody
  • tumor necrosis factor receptor superfamily, member 17 (Tnfrsf17) antibody
  • BCM antibody
  • BCMA antibody
  • CD269 antibody
  • Tnfrsf13 antibody
  • Tnfrsf13a antibody
  • TNFRSF17 antibody

Protein level used designations for TNFRSF17

tumor necrosis factor receptor superfamily member 17 , tumor necrosis factor receptor superfamily, member 17 , B cell maturation antigen , B-cell maturation factor , B-cell maturation protein

GENE ID SPECIES
287034 Rattus norvegicus
467905 Pan troglodytes
712212 Macaca mulatta
608 Homo sapiens
21935 Mus musculus
Selected quality suppliers for anti-TNFRSF17 (TNFRSF17) Antibodies
Did you look for something else?